FELIX BAKER
CIK 1087940 · last filed 2026-07-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.51B
Companies
31
Total Filings
291
Lifetime Open-Market Net
$1.52B
Filer Profile
Reported Address
BAKER BROS. ADVISORS LP860 WASHINGTON STREET 3RD FLOOR
NEW YORK, NY 10014
Related Filers
JULIAN BAKER — 1,520 joint filings, latest 2026-08-11
BAKER BROS. ADVISORS LP — 585 joint filings, latest 2026-08-11
Baker Bros. Advisors (GP) LLC — 553 joint filings, latest 2026-08-11
667, L.P. — 520 joint filings, latest 2026-08-11
Baker Brothers Life Sciences LP — 520 joint filings, latest 2026-08-11
Baker Brothers Life Sciences Capital (GP), LLC — 228 joint filings, latest 2012-03-14
14159, L.P. — 211 joint filings, latest 2019-10-03
14159 capital (GP), LLC — 203 joint filings, latest 2012-03-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CELC | 442,940 | $83.45 | $36.96M | -$1.27B | 1 | 2026-07-16 | |
| INCY | Director | 3,115,871 | $121.47 | $378.48M | -$15.68M | 30 | 2026-06-10 |
| KNSA | Director | 2,759,734 | $76.27 | $210.48M | $324.00M | 4 | 2026-06-02 |
| VTVT | Director | 12,368 | $31.97 | $395.4K | $0 | 2 | 2025-09-05 |
| MDGL | Director | 1,796,261 | $534.49 | $960.08M | $0 | 2 | 2025-06-24 |
| DBVT | Director | — | $11.85 | — | $0 | 1 | 2025-03-31 |
| ONC | Director | 730,643 | $346.51 | $253.18M | -$1.14B | 1 | 2025-02-28 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 3,123,770 | $1.27 | $3.97M | $20.59M | 2 | 2024-03-14 |
| Neurogene Inc. (NLTX) Delisted | Director | 39,081 | $13.96 | $545.6K | $38.80M | 3 | 2023-10-10 |
| TRDA | 10%+ Owner | 360,122 | $6.80 | $2.45M | $2.77M | 2 | 2022-06-06 |
| KOD | Director | 14,393,675 | $32.89 | $473.41M | $436.10M | 5 | 2022-02-17 |
| Talis Biomedical Corp (TLIS) Delisted | Director | 470,212 | $2.84 | $1.34M | $1.31M | 1 | 2021-11-19 |
| Seagen Inc. (SGEN) Delisted | Director | 4,124,966 | $228.74 | $943.54M | $2.56B | 33 | 2021-05-18 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 18,590 | $184.71 | $3.43M | -$160.29M | 1 | 2021-01-06 |
| PRLD | Director | 9,247,763 | $4.59 | $42.45M | $180.00M | 1 | 2020-09-30 |
| Atreca, Inc. (BCEL) Delisted | 10%+ Owner | — | $0.15 | — | $0 | 1 | 2020-07-20 |
| Neurogene Inc. (AQXP) Delisted | Director | 1,178,742 | — | — | $6.69M | 1 | 2019-08-08 |
| Aceragen, Inc. (IDRA) Delisted | Director | 5,249 | $7.22 | $37.9K | -$20.91M | 14 | 2019-04-03 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 185,836 | — | — | -$232.16M | 49 | 2019-03-19 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 3,054,192 | $58.70 | $179.28M | $0 | 1 | 2016-04-01 |
| BCRX | 10%+ Owner | 2,145,586 | $8.12 | $17.42M | $7.12M | 7 | 2016-02-09 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 50,111 | — | — | $270.67M | 14 | 2015-06-22 |
| ACAD | Director | 1,468,014 | $27.83 | $40.85M | $201.38M | 3 | 2013-06-11 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 116,454 | — | — | $93.93M | 18 | 2012-02-03 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 9,840,469 | — | — | $219.64M | 22 | 2011-12-16 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | 72,731 | — | — | -$7.68M | 5 | 2011-08-03 |
| RPRX | 10%+ Owner | 1,608,196 | $58.61 | $94.26M | $4.61M | 2 | 2010-06-02 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | 10%+ Owner | 83,205 | — | — | $14.68M | 15 | 2009-02-06 |
| NEUROGEN CORP (NRGN) Delisted | Director | 690,856 | — | — | $0 | 12 | 2008-11-13 |
| TAPESTRY PHARMACEUTICALS, INC (TPPH) Delisted | 10%+ Owner | 41,120 | — | — | -$173 | 1 | 2008-04-08 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 502,680 | — | — | -$7.15M | 10 | 2007-12-07 |
Recent Filings · Page 23 of 30
291 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-04-15 | NEUROGEN CORP (NRGN) Delisted | Buy (P) | — | $0 | EDGAR |
| 2008-04-15 | NEUROGEN CORP (NRGN) Delisted | Buy (P) | — | $0 | EDGAR |
| 2008-04-08 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Buy (P) | +2,259 | $30.0K | EDGAR |
| 2008-04-08 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Buy (P) | +939,507 | $12.48M | EDGAR |
| 2008-04-08 | TAPESTRY PHARMACEUTICALS, INC (TPPH) Delisted | Sell (S) | −1,563 | -$173 | EDGAR |
| 2008-03-18 | NEUROGEN CORP (NRGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-03-17 | VIROPHARMA INC (VPHM) Delisted | Buy (P) | +178,131 | $1.54M | EDGAR |
| 2008-03-17 | VIROPHARMA INC (VPHM) Delisted | Buy (P) | +474 | $4.1K | EDGAR |
| 2008-03-14 | Seagen Inc. (SGEN) Delisted | Buy (P) | +16,509 | $132.7K | EDGAR |
| 2008-03-14 | Seagen Inc. (SGEN) Delisted | Buy (P) | +1,392 | $11.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.